Search Results

Displaying Results 1-2 of 2 "'BRTX'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

Jul 20, 2026, 10:31 ET Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

therapies. Emerging pipeline candidates, including SB-01 (Spine Biopharma), IDCT (DiscGenics), Rexlemestrocel-L (Mesoblast and Grünenthal), AMG0103 (AnGes), BRTX-100 (BioRestorative Therapies), and others, are reshaping the DDD market landscape. LAS VEGAS,

More news about: DelveInsight Business Research, LLP

May 27, 2026, 07:45 ET Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing

More news about: KAOS Capital

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.